Today: 9 June 2026
Chevron stock price rises as oil rallies; OPEC+ meeting and Lukoil talks loom
28 February 2026
2 mins read

Chevron stock price rises as oil rallies; OPEC+ meeting and Lukoil talks loom

New York, February 27, 2026, 19:05 EST — After-hours

Chevron Corp (CVX.N) finished Friday up 1.41% at $186.76 in New York. Shares have climbed roughly 23% year-to-date.

Chevron tracked the climb in crude. Brent finished 2.45% higher at $72.48 a barrel, while U.S. crude picked up 2.78% to close at $67.02, after nuclear negotiations between the U.S. and Iran dragged on into next week with no breakthrough. “Uncertainty prevails, fear is pushing prices higher today,” said Tamas Varga, oil analyst at PVM brokerage. Reuters

Deal chatter gave traders more to chew on. Citing an Office of Foreign Assets Control document, Reuters reported that Washington has moved the deadline for would-be buyers of Lukoil’s overseas assets out to April 1. A Chevron collaboration with Texas-based Quantum Capital Group is in the mix for the assets, which sources peg around $22 billion.

Iraq’s oil minister said production at the massive West Qurna 2 field might jump to 750,000–800,000 barrels a day if Chevron steps in to run operations after Lukoil. The potential handover still requires sign-off, the minister noted. According to Reuters, Chevron hasn’t replied to a request for comment.

Beyond energy, inflation data weighed on the wider market. U.S. producer prices climbed 0.5% in January, signaling more wholesale inflation. “Wider margins for producers could add some upside for consumer costs in coming months,” said Ben Ayers, senior economist at Nationwide. Reuters

The S&P 500 slipped 0.43% Friday, while the Dow dropped a sharper 1.05%, with investors mulling concerns over stretched valuations and the potential fallout from artificial intelligence on company fortunes. Energy stocks managed to hold up better than most.

Exxon Mobil moved up 2.67%. Valero Energy saw a smaller uptick, adding 0.42%. Marathon Petroleum headed the other way, down 1.42%, according to MarketWatch data.

Still, crude’s risk premium—the cushion built in for potential supply shocks—tends to disappear quickly. Barclays notes that Brent might shed $3 to $5 a barrel without a major disruption, though the bank says a jump to $80 is possible if outages take hold.

Chevron is promising both production growth and more money back for shareholders. On Jan. 30, the company projected its 2026 output would climb 7% to 10%, not counting any divestments—thanks in large part to its projects in Guyana and the U.S. Gulf of Mexico. “As we look for opportunities to grow, we will stay disciplined around capital,” CFO Eimear Bonner told analysts during the earnings call. Reuters

There’s now a date for Chevron’s next dividend. The company bumped its quarterly payout up 4%, to $1.78 per share. Investors holding shares as of Feb. 17 will get paid on March 10.

Macro investors are eyeing the upcoming Personal Consumption Expenditures (PCE) price index, the Federal Reserve’s preferred measure of inflation, set for release on March 13.

Energy traders won’t have to wait long for fresh headlines. OPEC+—that’s Saudi Arabia, the UAE, and other oil heavyweights—gathers this Sunday, March 1. Reuters says the group is eyeing a 137,000 bpd output bump for April. “The boost in exports will definitely create a short-term buffer of any Strait of Hormuz disruptions and/or any shipping companies deciding to avoid the region,” TP ICAP analyst Scott Shelton told Reuters. Reuters

Stock Market Today

  • Docebo (TSX:DCBO) Valuation Story Shifts Amid Revised Earnings Guidance
    June 9, 2026, 10:40 AM EDT. Docebo's fair value remains at CA$35.97 despite updated financial models, reflecting a recalibration of valuation assumptions. Analysts highlight contrasting bullish views, citing a clear growth story backed by recent revenue guidance raising full-year 2026 estimates to US$271-275 million, against bearish concerns over limited analyst coverage and potential risks. The e-learning software provider forecast revenue of approximately US$65.4-65.6 million for Q1 2026, and US$66.7-66.9 million for Q2. At its Inspire 2026 event, Docebo unveiled a next-generation learning platform and key product updates, signaling strategic progress. Investors should monitor shifting assumptions and sector context amid evolving market narratives.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Oracle (ORCL) stock price drops as AI-spending doubts bite again, with March earnings next test
Previous Story

Oracle (ORCL) stock price drops as AI-spending doubts bite again, with March earnings next test

Borsa Istanbul’s BIST 100 ended the week lower — here’s what matters before Monday’s open
Next Story

Borsa Istanbul’s BIST 100 ended the week lower — here’s what matters before Monday’s open

Go toTop